Tag: acquisition

August 31, 2023

The transaction gives the Danish drugmaker full rights to develop and commercialise Embark Biotech’s lead asset targeting obesity and other cardiometabolic diseases. In exchange, Embark Biotech will receive an upfront cash payment of €15m and will also be eligible to […]

January 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium […]

December 28, 2022

In pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma […]

December 9, 2022

Gilead placed a major bet on cell therapy with its $12 billion acquisition of Kite in 2017. To the frustration of some investors, the business took several years to ramp up. But sales have substantially grown in recent months. Gilead’s […]

November 30, 2022

AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies. Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor […]

August 19, 2020

Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash. This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a […]